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Abstract
Background: Breast cancer is the most commonly diagnosed malignancy in women. Mastectomy and breast-
conserving surgery (BCS) have equivalent survival for early stage breast cancer. However, each surgery has different
benefits and harms that women may value differently. Women of lower socioeconomic status (SES) diagnosed with
early stage breast cancer are more likely to experience poorer doctor-patient communication, lower satisfaction with
surgery and decision-making, and higher decision regret compared to women of higher SES. They often play a more
passive role in decision-making and are less likely to undergo BCS. Our aim is to understand how best to support
women of lower SES in making decisions about early stage breast cancer treatments and to reduce disparities in
decision quality across socioeconomic strata.
Methods: We will conduct a three-arm, multi-site randomized controlled superiority trial with stratification by SES
and clinician-level randomization. At four large cancer centers in the United States, 1100 patients (half higher SES
and half lower SES) will be randomized to: (1) Option Grid, (2) Picture Option Grid, or (3) usual care. Interviews,
field-notes, and observations will be used to explore strategies that promote the interventions’ sustained use and
dissemination. Community-Based Participatory Research will be used throughout. We will include women aged at
least 18 years of age with a confirmed diagnosis of early stage breast cancer (I to IIIA) from both higher and
lower SES, provided they speak English, Spanish, or Mandarin Chinese. Our primary outcome measure is the 16-item
validated Decision Quality Instrument. We will use a regression framework, mediation analyses, and multiple
informants analysis. Heterogeneity of treatment effects analyses for SES, age, ethnicity, race, literacy, language,
and study site will be performed.
Discussion: Currently, women of lower SES are more likely to make treatment decisions based on incomplete or
uninformed preferences, potentially leading to poorer decision quality, quality of life, and decision regret. This
study hopes to identify solutions that effectively improve patient-centered care across socioeconomic strata and
reduce disparities in decision and care quality.
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Background
Breast cancer is the second leading cause of death in
women [1, 2]. Despite significant improvements in over-
all breast cancer survival, disparities persist in breast
cancer treatment, communication in healthcare, long-
term health outcomes and mortality [3, 4]. Women of
lower socioeconomic status (SES) diagnosed with early
stage breast cancer (I to IIIA) report significantly poorer
communication with their clinicians, lower knowledge of
breast cancer surgery options, higher uptake of mastec-
tomy, and worse cancer-related and patient-centered health
outcomes compared to women of higher SES [3–11]. They
also tend to receive breast cancer care that deviates from
established clinical guidelines (e.g., inconsistent use of radi-
ation after breast conserving surgery) [4, 10].
SES-linked differences in early stage breast cancer care
meet the Institute of Medicine’s definition of a health
service disparity [3, 9, 12, 13]. For early stage breast can-
cer, lower SES is a stronger predictor of poor outcomes
and treatment received than race or ethnicity [14, 15].
Treatment disparities are associated with patient-, clin-
ician-, and system-level factors [16, 17]. The reasons
women of lower SES are more likely to choose mastec-
tomy over breast conserving surgery (BCS) are not well
defined [8]. Limited financial resources and lack of in-
surance coverage do not always predict decision-making
for early stage breast cancer surgery [18]. Moreover, BCS
has higher short-term cost but lower long-term cost
[19]. For many women of lower SES, Medicaid, Medi-
care, and other programs will cover the costs of either
treatment, thus minimizing the impact of treatment cost
on decision-making. Patient-level factors, such as child-
care, transportation expenses, and financial pressures
(e.g., a need to return to work quickly) may be strong in-
fluences on treatment choices as well. However, the
exact impact of these factors remains unclear [20, 21].
Although BCS is a recommended treatment for early
stage breast cancer, research confirms equivalent sur-
vival between mastectomy and BCS [22–25]. Both op-
tions are offered routinely yet have distinct harms and
benefits that patients may value differently [26]. In this
context, patient preferences play an essential role in
decision-making. According to the Institute of Medicine,
shared decision making (SDM) should be promoted to
improve the quality of health care, particularly for can-
cer care [27–31]. However, only 44 to 51% of women
with early stage breast cancer across socioeconomic strata
achieve the degree of participation in decision-making
they desire [5, 6, 32–35]. Women of lower SES are more
likely to play a passive role in decision-making and to have
higher decision regret following surgery than women of
higher SES [4, 5, 8, 9, 11]. Surgeons may spend less time
communicating and engaging with patients of lower SES
[11, 36]. The relationship between SES, participation in
decision-making, and breast cancer disparities is robust
[3, 4, 7, 9, 10, 12].
Patient decision aids may help reduce those disparities
by providing evidence-based information about the harms
and benefits of options to help patients deliberate about
their preferences [37]. Patient decision aids for breast can-
cer surgery reduce decisional conflict, increase knowledge
and satisfaction with the decision-making process, and, in
some instances, increase BCS uptake and quality of life
[38–40]. However, decision aids are often designed for
highly literate audiences, may have poor accessibility and/
or readability, and may not be tailored to the needs of indi-
viduals of low SES and low health literacy [38, 39, 41–46].
All but one breast cancer decision aids were evaluated
solely in women of higher SES [47]. Shorter, simpler deci-
sion aids designed for use in clinical encounters—encoun-
ter decision aids—may be more beneficial to underserved
patients, provided they are developed to meet the needs of
these patients [41, 42, 48]. Encounter decision aids can in-
crease patients’ knowledge and participation in decision-
making, improve risk perception, and, in some instances,
influence choice and improve adherence to treatments
[49–54]. They have been successfully used by clinicians,
do not increase consultation time, and are becoming
routinely adopted in usual care through the electronic
medical record [51, 55–57]. However, the effect of encoun-
ter decision aids among patients of lower SES and lower
health literacy, to potentially reduce disparities across so-
cioeconomic strata, has never been evaluated.
The three aims of our study will be realized in the
context of the logic model shown in Fig. 1.
Aim 1
Assess the comparative effectiveness of two effective en-
counter decision aids (Option Grid and Picture Option
Grid) against usual care on SDM, decision quality, treat-
ment choice and other direct outcomes in women, and
differentially by SES.
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Hypothesis 1.1
The encounter decision aids will increase SDM in the
clinic visit and improve decision quality, knowledge, and
quality of life in women of higher and lower SES com-
pared to usual care. We also anticipate that they will
reduce decision regret and improve the perceived inte-
gration of healthcare delivery (see Fig. 1).
Hypothesis 1.2
The Picture Option Grid will be more effective than the
Option Grid at improving primary and secondary out-
comes in women of lower SES. There will be no differ-
ence between the effects of the two encounter decision
aids in women of higher SES.
Aim 2
Measure the effect of the Picture Option Grid on dispar-
ities in decision-making (decision quality, knowledge, and
SDM) and treatment choice, and conduct an exploratory
analysis of the mediation and moderation effects.
Hypothesis 2.1
Compared to the Option Grid and usual care arms, the
Picture Option Grid will reduce disparities in decision
quality, knowledge, and participation in SDM between
women of lower and higher SES. It is also likely to re-
duce disparities in treatment choice.
Hypothesis 2.2
The effect of the Picture Option Grid on treatment
choice will be mediated by post-intervention knowledge,
SDM, and post-intervention values (reported in ‘What
Matters Most to You’ subscale of DQI, e.g., keeping
breast, removing breast to gain peace of mind, avoiding
radiation, etc.) (see Fig. 2).
Hypothesis 2.3
For women of lower SES, socioeconomic barriers (e.g.,
resource constraints, as reported in the Decision Quality
Instrument) will affect treatment choice and thereby
moderate the intervention’s effect.
Fig. 1 Logic model of proposed study. *See Fig. 4 for mediation pathways. Legend: blue text = Personal level factors according to Cooper’s framework,
green text = Clinician & system level factors according to Cooper’s framework, - - - - outline = outputs and outcomes of the randomized controlled trial
Fig. 2 Causal model for patients enrolled in the trial. Legend: Arrows depicted in green, red and blue represent causal relationships of one variable on
another. The presence of green arrows will be examined in Aim 1. The presence of blue arrows (mediation effects) and red arrows (moderation effects)
will be examined in an exploratory analysis in Aim 2
Durand et al. BMC Public Health  (2018) 18:241 Page 3 of 16
Aim 3
Explore strategies that promote the encounter decision
aids’ sustained use and dissemination using a theoretical
implementation model.
Hypothesis 3.1
Pre-visit planning, minimal clinician training, flexibility
of use, and integration into the workflow and EMR will
facilitate sustained use.
Hypothesis 3.2
Successful use by patients and their families will be de-
termined by the perceived acceptability of the interven-
tion and integration into workflows.
Methods
This clinical trial protocol follows the SPIRIT guidelines
(see Additional file 1) and CONSORT statement [58, 59].
Design
We will use a three-arm, multi-site randomized con-
trolled superiority trial with stratification by SES and
parallel study design. Over a 16-month period, we will
recruit 1100 patients (half higher SES and half lower
SES) (Fig. 3). Randomization will be at the clinician
level, nested within study sites, and will involve data
analyst blinding. At each site, we will use a cross-
sectional study design and randomize participating clini-
cians to one of three arms (Option Grid, Picture Option
Grid, or usual care) using an R script written by the
study statistician. Balanced block randomization will be
used to account for the varying number of physicians at
each site. Patients who have given informed consent and
are seeing one of the participating clinicians will be allo-
cated to the clinician’s corresponding arm. In Year 1, we
will adapt the “What Matters Most to You” subscale of
the Decision Quality Instrument (DQI) for women of
lower SES. For Aim 3, we will use interviews with trial
participants, healthcare professionals, and other relevant
stakeholders, field-notes, and observations to explore
strategies that promote the encounter decision aids’ sus-
tained use and dissemination. Community-Based Partici-
patory Research (CBPR) will be used throughout the trial.
Controlling for contamination
Since the randomization occurs at the clinician level, we
are confident that the risk of contamination will be min-
imal [60]. However, to control for any potential contam-
ination and assess the fidelity of delivering each
intervention, we will audio-record clinical encounters
with patients who have consented to have their consult-
ation recorded (see consent process in section Data
management and analysis). At T2, we will ask all patients
to indicate which intervention was introduced to them.
We will use both intention-to-treat and as-treated ana-
lyses. We will train all clinicians in delivering the interven-
tion according to their allocated arm (see section
Monitoring for clinician training). Clinicians in usual care
will not be trained in the use of the interventions. If there
is residual contamination, the bias will be towards a null
effect. We will therefore be confident that any significant
findings are actual.
Setting
In order to ensure that study participants are representa-
tive of the target population, the study will be conducted
at four large cancer centers in the United States located in
Fig. 3 CONSORT* study flow diagram. *CONSORT stands for Consolidated Standards of Reporting Trials, as reported in the CONSORT statement
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geographically diverse regions that provide a combination
of urban and rural settings as well as racially and ethnic-




Insurance status will be used to screen for higher and
lower SES (lower SES: uninsured, on Medicaid or Medi-
care without supplemental insurance or ACA Marketplace
plans; higher SES: privately insured or on Medicare with
supplemental insurance). At baseline, we will collect infor-
mation about median household income, household size,
and highest educational attainment (self-reported). We
will use household income and highest educational attain-
ment to measure SES, in combination with insurance sta-
tus (using multiple informants analysis). This approach is
acceptable and recommended by experts [61–63].
Randomized controlled superiority trial (aims 1 and 2)
We will recruit 1100 women at least 18 years of age with
a confirmed diagnosis of early stage breast cancer (I to
IIIA) over 16 months. Approximately half will be from
the lower SES population, and about half will be from
the higher SES population.
Participant Inclusion Criteria
 Assigned female at birth;
 At least 18 years of age;
 Confirmed diagnosis (via biopsy) of early stage
breast cancer (I-IIIA);
 Eligible for both breast-conserving surgery and
mastectomy based on medical records and clinician’s
opinion before surgery;
 Spoken English, Spanish, or Mandarin Chinese.
Participant Exclusion Criteria
 Transgender men and women;
 Women who have undergone prophylactic
mastectomy;
 Women with visual impairment who might have
difficulty viewing the decision aids;
 Women with a diagnosis of severe mental illness or
severe dementia;
 Women with inflammatory breast carcinoma.
Women who are receiving neoadjuvant therapy will be
invited to participate in the first 9 months of the trial in
order to complete follow-up assessments before the trial
terminates. T3 assessments will occur after neoadjuvant
therapy and post-surgery. This may occur up to 7
months after T0 (baseline).
Feasibility of recruitment
We aim to recruit 275 patients at each site (this number
may vary depending on stratification and patient volume).
To facilitate recruitment, a patient associate will be
employed at each site throughout the study. The patient
associate will be a patient who has had breast cancer and
has completed all treatments. She will be involved in the
trial to promote patient-centeredness and facilitate re-
cruitment among women of lower SES. The patient asso-
ciate will be CITI certified and trained to consent and
recruit participants. The Institutional Review Boards have
no concerns about the involvement of a patient associate
who has completed all breast cancer treatments (see
section Tracking and retaining participants for tracking
and retention of participants).
Interventions and comparators
The interventions are paper-based and range from one
to four pages in length. The Option Grid was written in
plain language but was not specifically designed for
women of lower SES (Flesh-Kincaid grade level of 6.6).
The Picture Option Grid (specifically designed for
women of lower SES and lower health literacy) has a
Flesh-Kincaid grade level of 6.5. Both interventions will
be used by the surgeon during the surgical consultation.
By using the same medium and delivery mode, we en-
able a direct comparison. Both interventions have been
developed, tested, and validated [51, 64–68].
Intervention 1: Option grid
The Option Grid™ encounter decision aid for early stage
breast cancer surgery is a one-page, evidence-based sum-
mary of available options in a tabular format (Additional
file 2). The efficacy of Option Grid decision aids has been
tested in a stepped wedge trial, where they were shown to
increase patients’ knowledge and SDM in the clinic visit
[51]. Similar results were achieved using qualitative
methods [55, 57, 69, 70]. Option Grid decision aids are
used in routine clinical practice and downloaded over
5000 times a month (http://www.optiongrid.org/). The
Option Grid for breast cancer surgery was developed in
2010 and downloaded 1346 times in 2016. It was ini-
tially adapted from a web-based decision aid shown to
facilitate readiness to decide and strengthen surgery in-
tentions [67, 68].
Intervention 2: Picture option grid
The Picture Option Grid was derived from the Option
Grid for early stage breast cancer (see Additional file 3).
It uses the same evidence but integrates images and sim-
pler text in order to exploit picture superiority [71, 72].
The Picture Option Grid has been specifically designed
for women of lower SES and lower health literacy. It
was iteratively developed and tested in underserved
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community settings with lay women (without breast
cancer) and breast cancer patients of lower SES using
CBPR [66]. We have tested its acceptability, feasibility,
and perceived impact in 278 women of lower SES diag-
nosed with early stage breast cancer and with health
professionals, comparing it to the Option Grid and to a
comic strip encounter decision aid [65]. Most women
of lower SES and health professionals deemed the Pic-
ture Option Grid most acceptable and usable.
Comparator
Because decision aids are not routinely available in clin-
ical settings, usual care is a legitimate comparator. For
the purpose of this trial, usual care will include the
provision of typical information resources about breast
cancer that are currently available at each study site.
These resources differ across study sites. To capture dif-
ferences, we will collect detailed information about usual
care at each site using methods derived from ethnog-
raphy and will include questions about usual care at T2.
Outcomes
To accommodate varying levels of literacy and health lit-
eracy of our target group, we will use validated short-
form questionnaires whenever possible. Aside from the
Observer OPTION5 scale [73], all are patient-reported
outcome (PRO) or patient-reported experience (PRE)
measures. All included scales and tests other than the
demographic questions have been validated.
Primary outcome measure
The primary outcome measure (see Table 1) is the vali-
dated 16-item Decision Quality Instrument (DQI) for
breast cancer, which includes a knowledge subscale [74]
(in the full trial protocol, available upon request). The
DQI, designed to be administered post-decision, will be
assessed at T2 and T3. It aims to measure the extent to
which patients are informed about their options, are in-
volved in the decision-making process, and receive a sur-
gery (mastectomy or BCS) aligned with their values,
attitude towards risks, and preferences. It produces three
scores: (1) knowledge, (2) concordance, and (3) decision
process [74].
Secondary outcome measures
Secondary outcome measures will include treatment
choice (assessed at T3 using patients’ medical records),
treatment intention, CollaboRATE (the validated three-
item measure of SDM) [75, 76], Chew’s validated one-
item health literacy screening question [77], PROMIS,
an eight-item validated short form measure of anxiety
[78], EQ-5D-5 L, the validated, standardized six-item
quality of life measure [79], the five-item validated deci-
sion regret scale [80], and four items from COST, a
validated financial toxicity measure [81, 82]. We will also
ask participants to estimate the out-of-pocket (OOP) por-
tion of their medical expenses over the past month. We
will use the recordings of clinical encounters (see section
Controlling for Contamination) to analyze the extent to
which SDM occurs using the five-item validated observer-
rated OPTION5 scale [73]. We will include a fidelity-of-
use checklist derived from Wyatt’s work to assess the ac-
tual use of encounter decision aids [48]. Finally, we will
use IntegRATE, a four-item generic patient-reported
measure of integration of healthcare delivery [83]. At T2
and T3, we will investigate each intervention’s patterns of
use. At T2, the research team will take a picture of each
intervention post-consultation to determine how the
intervention has been used and whether the patient/family
and/or clinician have annotated it. At T3, participants will
be asked to indicate how many times they have used the
intervention and whether family members, relatives, or
caregivers have used the intervention.
Translation procedures
All study documents, interventions, and measures that
are not currently available in Spanish and Mandarin
Chinese will be translated using standard translation
procedures successfully implemented before [84]. Span-
ish and Mandarin Chinese interpreters or ‘language
lines’ will be available at each site before, during, and
after the clinic visit.
Sample size and power calculation
For Aim 1, hypothesis 1, we base the effect size estimation
on published data from randomized controlled trials of
decision aids for breast cancer surgery [38, 39, 85, 86],
suggesting that a reasonable effect size for DQI is 9.34,
that the standard deviation between patients in the
intervention arms compared to usual care is 12.00, and
that a within-physician intra-class correlation (ICC) of
0.05 is reasonable. This ICC is justified because treat-
ment varies within study site, thereby allowing hetero-
geneity that occurs between physicians across centers
to be blocked. We assume a patient attrition rate of
20%. Under these assumptions, a study of 1100 partici-
pants (68.75 participants per physicians and 366.66 per
treatment group) has power of greater than 99.8% to re-
ject the null hypothesis that the encounter decision aid
groups and the control group have equal means, using a
two-sided 0.05 level test when the true mean difference is
9.34. For hypothesis 2, because we anticipate obtaining a
similar number of women in the higher and lower SES
categories, the same power calculation is performed on a
sample size of half the size. With 550 patients in total
(34.375 patients on average per physician), under the same
assumptions as above, the power for this subgroup test is
99% with ICC = 0.05 and with ICC = 0.175.
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For Aim 2, the power of the test for disparities be-
tween higher and lower SES is necessarily lower than
the overall test at the same effect size, as four groups
are compared (Picture Option Grid higher SES, Pic-
ture Option Grid lower SES, Option Grid and usual
care higher SES, Option Grid and usual care lower
SES). However, because patient SES varies within
physician, power can be conservatively computed as if
the patient-level variance was doubled and the total
number of patients halved. If the true difference in
the effect of the Picture Option Grid on decision
quality between the higher and lower SES groups is
8.5 compared to Option Grid or compared to usual
care, the power for a two-sided alpha-level test at the
0.05-level is just above 80%. A significant finding is
even more likely to be obtained if the estimated vari-
ability in the data turns out to be much smaller than
assumed here. It is not critical to account for multiple
testing because in both the primary (Aim 1) and second-
ary (Aim 2) analyses, a single pair of groups is compared.

















Allocation (via surgeon confirmation) X
INTERVENTIONS
Arm 1: Option Grid X
Arm 2: Picture Option Grid X
Arm 3: Usual Care X
OUTCOME MEASURES
Rates of recruitment – documented and tracked in REDCap X
Discontinuation rates – documented and tracked in REDCap X X X X X
Demographic data – 6 items, self-reported X
Health literacy – 1-item Chew’s health literacy screening X
Decision quality (primary outcome measure) – validated 16-item DQI,
subscale adapted for low SES
X X
Knowledge – validated 5-item DQI knowledge subscale X (X) (X)
Treatment intention – self-reported via DQI (X)
Treatment choice – obtained from medical records X
Quality of life – validated 6-item EQ-5D-5 L X X
Anxiety – validated 8-item PROMIS anxiety short form X X X X
Shared decision-making (observed) – validated OPTION5 X
Shared decision-making (self-reported) – validated 3-item CollaboRATE X
Decision regret – validated 5-item decision regret scale X X X
Integration of health care delivery – validated 4-item IntegRATE X X
Financial toxicity – four items from validated COST measure and
self-report of out-of-pocket medical expenses in the past month
X X X
Intervention’s patterns of use – questions and photos of intervention X X
System level factors + feasibility and acceptability in routine care
Ethnographic methods X X X X X
Semi-structured interviews X
PS post-surgery
(X) included in full DQI
aor first post-operative visit
bor second post-operative visit
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Screening, consent, and allocation
Screening for inclusion in the randomized controlled trial
At each study site, our research assistants will work with
the breast care team to identify eligible participants
in advance of each breast clinic. Insurance status
(self-reported or obtained via EMR) will be used to
screen for SES. For each participant, we will check
whether her income (in EMR or self-reported at
baseline) is consistent with the higher or lower SES
designation made at the initial screening, and reassign
if needed. As mentioned above, educational attainment
will also be collected but will not be used during the
recruitment process to determine allocation to the
higher or lower SES group.
Consent procedures
Eligible patients at Washington University in St. Louis will
receive an information sheet a few days before their
scheduled appointment. The information sheet will be
written using plain language and pictures to address the
needs of women of lower SES and low literacy/low health
literacy. At NYU School of Medicine, Montefiore Medical
Center, and Dartmouth-Hitchcock, the research assistant
will approach patients who are pre-screened for eligibility
on the clinic day to provide the information sheet and dis-
cuss the study prior to the surgical appointment. Consent
procedures will vary slightly at each site based on the pa-
tient flow and individual needs of each clinic. However, at
each site, the research assistant will be responsible for
obtaining written consent for participation in the trial (in-
cluding recording of clinical encounters and interviews).
The research assistant or patient associate will read the
questions to patients who cannot read or write by using
standardized interviewing procedures in a private room.
We will document whether a standardized interview was
conducted and whether the assistance of an interpreter
was needed (see Fig. 4 and full trial protocol available
upon request).
Assignment of interventions
Patients who have given informed consent and are seeing
one of the participating clinicians will be allocated to their
clinician’s corresponding arm (Option Grid, Picture Op-
tion Grid, or usual care). The intervention will be used
during the surgical consultation visit. In the usual care
condition, the patients will receive care as usual for their
respective study site. They will receive a study card at the
end of the consultation to signal to the research team that
the patient has been officially enrolled into the study.
We will monitor accrual at each site to ensure that a
similar number of patients is recruited in each socioeco-
nomic stratum and arm. Once the target number of par-
ticipants in each arm and each stratum has been
reached, recruitment of patients in this particular arm
and stratum will end. Recruitment will continue in other
arms and strata until all target numbers of participants
per group have been reached.
Changes to intervention allocation
There are no established criteria for discontinuing or
modifying the allocated intervention for study partici-
pants due to the low risk nature of the trial. If a partici-
pant requests to be put in a different arm, they will not be
able to take part in the study. Subjects will be free to with-
draw from the study at any time for any reason.
Baseline and follow-up assessments
The baseline assessment will happen prior to the first
surgical consultation visit. Follow-up assessments will
occur immediately after the surgical consultation (same
day), 1 week post-surgery, or at the first post-surgical
Fig. 4 Site-specific consent and baseline assessment procedures
Durand et al. BMC Public Health  (2018) 18:241 Page 8 of 16
clinic visit (T3), 12 weeks post-surgery, or at the corre-
sponding clinic visit (T4), and 1 year post-surgery (T5).
Baseline and follow-up assessments will be completed by
the research assistant or patient associate. They will be
done in person, online, over the phone using standard-
ized interview procedures, or via mail service.
Data management and analysis
Data management
Data management for the study will be done through
REDCap, a HIPAA-compliant web-based data manage-
ment system [87]. REDCap will be hosted at Dartmouth-
Hitchcock Medical Center (DHMC) for data collected at
DHMC. Data collected from all other sites will be hosted
on REDCap at Dartmouth College. Access will only be
granted to study team members designated to manage
the study data and will require a dedicated username
and password. Study team members at participating
study sites will only have access to data collected at their
institution. This database management system is de-
signed to comply with the ICH Good Clinical Practice
(GCP) guidelines.
Data entry into REDCap will be done by research as-
sistants and patient associates at each site using stan-
dardized data collection forms. Samples of the data
collection forms will be available in the full protocol
once they are finalized (available upon request).
In addition, each study site will have a data-protected,
encrypted external hard drive for the local storage of
sensitive study-related materials. Each of the study sites
will return the hard drives to Dartmouth College at the
end of the trial. Dartmouth College will store the
encrypted data for 6 years after the conclusion of the
trial, after which all data will be destroyed. Signed con-
sent forms will be kept in a locked file cabinet in a se-
cure location at each study site, and for 6 years after the
conclusion of the trial.
Data analysis
Initial examination of data will include descriptive statis-
tics, frequency distributions, and histograms in order to
identify outliers and missing data. Primary analyses will
be based on “intention-to-treat”, but an “as-treated” ana-
lysis based on participants’ report of the intervention re-
ceived, will also be undertaken.
Analysis corresponding to aim 1 We will first perform
separate analyses for each follow-up period using linear
and logistic regression models as appropriate for con-
tinuous (decision quality, SDM, quality of life, anxiety,
decision regret, and IntegRATE) and binary (treatment
choice) outcomes respectively. The results will provide po-
tentially valuable insights into how rapidly each interven-
tion affects outcomes. Outcomes measured multiple times
after T0 (anxiety, regret, decision quality, and financial
toxicity) may also be analyzed using a longitudinal model.
If the interventions are found to have an effect, a second-
ary analysis that adds predictors for the number of prior
Option Grid and Picture Option Grid patients seen by the
healthcare professional will examine whether there are
physician learning effects under either intervention.
We will adopt a regression framework for all analyses
as it allows seamless transition between basic analyses
involving a single predictor (or two indicators corre-
sponding to each intervention versus the comparator)
and more complex analyses involving additional predic-
tors (mediation variables, control covariates, time-trends,
interaction terms or effect modifiers). Further, the regres-
sion framework allows clustering of observations due to
repeated measurements on patients across time, nesting
of health professionals within sites, and patients within
health professionals, to be accurately accounted for using
mixed-effect regression models [88] or generalized esti-
mating equations [89, 90]. Multiple comparisons will be
accounted for using Scheffe’s method [91].
The secondary outcomes (SDM, anxiety, integration of
healthcare delivery, decision regret, quality of life and
financial toxicity) have in excess of 10 levels, and
they will be analyzed as continuous variables. To
assess whether the results of each analysis are trust-
worthy, we will analyze the residuals to check if the
assumptions of the model hold [92]. For treatment
choice, a clearly defined binary variable based on
medical record data, we will adapt the model to a logistic
regression model.
The three measures of baseline socioeconomic status:
(1) insurance status, (2) highest educational attainment,
and (3) median household income, will be analyzed sep-
arately for a multiple informants analysis [93] or, pro-
vided they are not excessively collinear, we will enter
them in the model together and test their combined ef-
fect. For income, we will use a poverty income ratio: the
ratio of household income accounting for household size
and poverty line published by the Census Bureau in that
calendar year [94]. To aid interpretation of our results,
we will report the consequence of a patient changing
from above median SES to below median SES, even if
for added precision, it makes sense to base significance
tests on continuous measures.
To gain insight into whether the Picture Option Grid
and Option Grid will be more effective in certain sub-
populations, we will add each SES measure and its inter-
action with the intervention indicator variables to the
model. If the SES intervention interaction is non-
significant, we will remove them from the model and
test if the overall effect of SES is significant. Otherwise,
we will perform stratified analyses of the interventions’
effects by SES status.
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Analyses corresponding to aim 2 A logistic regression
model will be used to test for differences between the
Picture Option Grid group and the usual care and
Option Grid groups in decision quality, knowledge, par-
ticipation in SDM, and treatment choice, within subpop-
ulations (higher SES versus lower SES). A reduction of
disparity due to the interventions will be claimed if the
effect of SES on outcomes is significantly smaller for the
Picture Option Grid group than for the other two
groups at follow-up. As for Aim 1, a linear regression
model will be used for the decision quality analysis while
an analogous set of other predictors will be included as
covariates in the model. The assumptions of the models
will be evaluated for adequacy using residual analysis
and other model fit diagnostics [92]. Our exploratory
mediation analyses seek to identify and explicate the
mechanism or process that underlies the relationship be-
tween the Picture Option Grid and a dependent variable
via the inclusion of a third explanatory variable, known
as a mediator variable (e.g., knowledge, values, SDM).
We are specifically interested in whether interventions
operate through the mediator as opposed to directly af-
fecting the outcome. We will perform these analyses
even if the findings from Aim 1 and Aim 2 (hypothesis 1)
are non-significant in order to determine whether the null
effect was due to a null effect of the intervention on the
mediator or a null effect of the mediator on the outcome.
To determine the generalizability of these mechanisms
and identify subpopulations for whom mediation is most
pronounced, we will compare the mediation effects across
different subgroups (e.g., higher SES versus lower SES).
The traditional and often-used approach to estimating
mediation effects is the causal steps approach, which ori-
ginated in Baron and Kenny (1986) [95]. However, due to
the limitations of that approach, we will estimate the me-
diation effect using the product of coefficients method
[96]. Standard errors will be evaluated using the bootstrap
[97] or the PRODCLIN program [98]. Software exists for
sensitivity analysis to violations of sequential ignorability
and other assumptions required for causality in mediation
analyses [99, 100]. We will apply this software and any
additional procedures available to our analyses in order to
obtain the most robust and defendable results.
Analyses corresponding to aim 3 We will use a frame-
work analysis, guided by Normalization Process Theory
(NPT) [101, 102], having successfully used this approach
previously [55, 70, 103, 104]. Observations and field-
notes will be included in the analysis. Initial descriptive
codes will be generated by two independent researchers
based on the four NPT constructs. In-vivo coding will
also be used to capture other naturally occurring ex-
changes. Categorical codes that group initial and in-vivo
codes will be developed in a third round of coding. In
addition, 100 photos of the interventions taken at T2 (ap-
proximately 50 of Option Grid and 50 of Picture Option
Grid) will be included in the analysis to answer questions
1 and 2. Triangulation of data will also be performed.
NPT was developed to understand how complex inter-
ventions become implemented in routine healthcare set-
tings [101, 102]. It is built around four theoretical
constructs: 1) Sense-making: processes of individual and
communal sense-making of a complex intervention re-
garding its use and value; 2) Participation: processes of
‘cognitive participation’ that promote or hinder users’
buy-in and commitment to the intervention; 3) Action:
processes of ‘collective action’ that determine or hinder
whether the intervention is being used by all as
intended; and 4) Monitoring: Processes of communal
and individual appraisal of the effect of the intervention.
We will use NPT as an analytical lens to consider the
data collected according to our hypotheses and the fol-
lowing five questions: (1) how the interventions were
perceived and used in and outside the clinical encounter
(including with family and caregivers), (2) preferred ways
for introducing and using the intervention in routine
clinical settings, from several perspectives: patients, fam-
ily, health professionals, administrators (3) perceived fit
in clinic workflow as well as reported barriers and facili-
tators to routine integration, (4) other perceived patient-,
physician- and system-level barriers and facilitators
to routine use, and (5) perceived generalizability and
feasibility in routine care.
Missing data
Most data collection will be via questionnaires (at T0,
T2, T3, T4, and T5), which provide opportunities for
preventing and monitoring missing data. We will offer
other formats for questionnaire completion (including
standardized interviews), thus minimizing missing data.
We will prompt each patient, by telephone, to complete
the follow-up questionnaires (at T3, T4, and T5) or
reach them in the clinic during their post-surgery ap-
pointments. Given the brevity of the trial and the proce-
dures described above, we do not anticipate more than
5% of missing data. However, should there be more than
a trivial amount of missing data, we will use multiple
imputation to cope with missing baseline, interim, and
outcome data (105). We will record and report all rea-
sons for dropout and missing data. This approach will
address both generalizability and causal validity bias. We
will also examine sensitivity of inferences.
Heterogeneity of treatment effects
The main goals of the heterogeneity of treatment effects
(HTE) analyses are to estimate treatment effects in clin-
ically relevant subgroups and to predict whether an indi-
vidual might benefit from exposure to the decision aid.
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As the HTE analyses are exploratory rather than
hypothesis-driven, exploratory subgroup analyses will be
conducted to identify hypotheses for future evaluation.
Patient characteristics will be considered for treatment
by covariate interactions and include SES, age, ethnicity,
race, literacy, language, and study site [105]. As de-
scribed in the analytic plans for testing interactions by
SES in Aims 1 and 2, interaction tests will be conducted
to determine if subgroup analyses of the intervention ef-
fects by the levels of that predictor are warranted. If the
interaction is significant, then the treatment effect is es-
timated separately at each level of the categorical vari-
able used to define mutually exclusive subgroups.
Access to complete dataset
Only the statistician and core research team will have
access to the final data set.
All data used in conducting the final analyses will be
made available in a de-identified copy for archival pur-
poses, and for collaborating researchers and organiza-
tions in no more than 9 months from the end of the
final analysis. We also plan to develop a Data Access,
Analysis, and Expression of Interest submission and re-
view process for formal requests to make use of the data,
thus preventing duplication in analysis and publication.
Given the data sharing plans, we will provide a detailed
description of these plans to all participants during the
informed consent process to ensure that participants are
aware of all potential uses of data.
Clinician training
All participating clinicians will receive training in using
the intervention they are randomized to, as well as how
to adhere to the trial protocol. This will include basic
shared decision making and communication skills train-
ing. We will use videos and role-plays. For clinicians
who are not able to attend a training session in person,




Enrollment will be monitored weekly at each site. The
number of patients screened by the breast-care team,
proportion eligible (and sent an information sheet), and
proportion consented and recruited in-clinic (according
to SES strata) will be documented on a screening log.
Where possible, reason for dropout will be recorded.
Adherence to protocol and supervision
To maximize adherence to the trial protocol, we will
train all co-investigators, research assistants, and patient
associates in recruiting patients according to the proce-
dures outlined in the protocol. The protocol will be
made available to all research team members and key
stakeholders in a password-protected section of the web-
site. Feedback will be provided to participating surgeons
and other members of the study team at each study site
as necessary, at 3 months, 6 months, and 12 months into
recruitment. To provide feedback to participating sur-
geons, we will use a preliminary analysis of the audio
recordings of randomly selected consultations across all
three arms as well as field-notes. Any proposed changes
will be discussed with the Trial Steering Group then
reported to PCORI, the Data and Safety Monitoring
Board (DSMB), IRB, and noted on ClinicalTrials.gov.
Trial management
Dartmouth College will have responsibility for central-
ized study management and general oversight. The re-
search team at Dartmouth will maintain all aspects of
the trial and work closely with each study site to coord-
inate all trial activities.
Trial steering group
A Trial Steering Group (TSG) will involve all key
personnel (including patient and stakeholder partners
and invited CAB members) and will meet every 3
months. The duties of the TSG will include supervising
the trial, monitoring trial progress, as well as reviewing
and acting on all DSMB recommendations.
Data and safety monitoring board
A Data and Safety Monitoring Board (DSMB) will be
appointed to provide additional oversight in the trial.
DSMB membership will comprise of seven members in-
cluding experts in the fields of shared decision making,
breast cancer surgery, patient advocacy, statistics, and
clinical trials methodology. The DSMB will operate inde-
pendently from the study sponsor. The DSMB charter is
available in the full trial protocol (available upon re-
quest). The DSMB will meet and review data bi-annually
throughout the project. The DSMB will review the
protocol, data collected to date (interim analyses every
6 months), and advise the PI on any potential risks and
risk mitigation plans. We do not expect any Serious Ad-
verse Events (SAE) or Adverse Events (AE) that would
require immediate reporting. However, some patients,
particularly those with diagnosed mental illness or pa-
tients who are finding it difficult to cope with their re-
cent cancer diagnosis, may find it stressful to be
randomized to one of the study arms. The DSMB will
therefore review data on subject withdrawals from the
study and stated reasons for withdrawal as well as study
subject anxiety scores (measured using PROMIS) for each
withdrawal. A detailed plan for identifying and reporting
participants who may be experiencing heightened anxiety
leading to withdrawal is provided in the full protocol (see
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supplemental file full trial protocol). If for any reason, an
SAE or AE were reported, the IRB at Dartmouth College
would be immediately notified as well as the appropriate
safety board at the participating sites. The DSMB would
convene urgently and review the SAE/AE.
Tracking and retaining participants
The research assistant or patient associate employed at
each site will track participants and ensure that they are
called in advance of the follow-up assessments and pro-
vided with a questionnaire in the format of their choice.
Interpreter services will be used whenever necessary.
Telephone calls will also be made by the patient associ-
ates whenever they are available.
Retention among patients of lower SES will be maxi-
mized by:
– Using short-form validated measures;
– Translating those measures into Spanish and
simplified Mandarin Chinese;
– Using interpreter services whenever necessary;
– Calling all participants 2-5 days before each follow-
up assessment is due, prompting patients to
complete the questionnaires and offering to conduct
a standardized interview over the phone. The latter
is likely to be particularly helpful in patients of
lower SES and lower literacy/health literacy;
– Conducting follow-up assessments in-person when
possible;
– Giving patients a choice of questionnaire format
for the completion of baseline and follow-up
assessments (online, paper-based, or standardized
interviews);
– Compensating participants for their time. Brueton et
al. identified monetary incentives as an effective way
of improving participant retention [106].
Ethics and dissemination
Ethical approval has been sought for Montefiore Medical
Center and Dartmouth-Hitchcock through Dartmouth
College’s Committee for the Protection of Human Sub-
jects (CPHS) (ref: STUDY00030157). Dartmouth College
CPHS approved the study on June 8, 2017. Montefiore
Medical Center Institutional Review Board (IRB) provided
authorization agreement to rely on review by Dartmouth
College on September 8, 2017. Ethical approval for Wash-
ington University in St. Louis was provided by The Wash-
ington University in St. Louis IRB on May 9, 2017 (ref:
201,704,011). NYU School of Medicine IRB provided
ethical approval on August 29, 2017 (ref: i17-00871).
The study outputs will likely interest a wide variety of
target audiences, ranging from patient and advocacy
groups, healthcare professionals, and healthcare organi-
zations to academics, policy makers, and decision aid
developers. Since the interventions are easily accessible
and inexpensive to update and disseminate, implementa-
tion in routine care could occur immediately post-project
completion. We plan to disseminate findings through the
following channels: academic, patient and advocacy organi-
zations, professional organizations and healthcare delivery
systems, social media and lay press, and dissemination
symposia and clinician training modules (see more infor-
mation in full trial protocol supplementary file). For aca-
demic outputs, we will follow ICMJE authorship guidelines.
Discussion
Our study addresses an important research and im-
plementation gap by evaluating two strategies for en-
gaging all patients, and particularly those of lower SES,
to reduce disparities. If this study shows the advantage
of the Option Grid and/or Picture Option Grid, dissem-
ination of those interventions could improve decision
quality, knowledge, quality of life, and other outcomes
while promoting informed treatment choice irrespective
of SES and health literacy, compared to usual care.
We anticipate that findings could be reproduced and
the intervention(s) adopted by clinicians in clinical prac-
tice to rapidly improve delivery of care. We will investi-
gate in Aim 3 how to facilitate this process, address
potential obstacles to routine use, and support clinicians
in implementing the intervention(s). We anticipate that
the study outcomes have the potential to change the way
clinicians inform and support patients in making breast
cancer surgery decisions. The study findings will be
beneficial to clinicians, policy makers and other national
and community stakeholders who aim to engage under-
served patients to improve outcomes across socioeco-
nomic strata to reduce disparities. The findings will
directly benefit patients, their families and caregivers, as
well as inform academics and decision aid developers who
strive to produce interventions that are beneficial to all
and can be effectively implemented in routine care.
Practical or operational issues involved in performing the
study
First, if the interventions do not show all hypothesized
effects but demonstrate, at the minimum, an effect on
SDM and knowledge (expected, based on preliminary
data), we will undertake Aim 2 and focus on the medi-
ation analysis and impact on disparities in knowledge
and decision-making. Second, we will address potential
imbalance in SES by monitoring SES accrual at each site,
for both control and intervention groups. Third, given
the expansion of the Affordable Care Act, insurance sta-
tus might not always be an accurate proxy for SES. To
solve this problem, we will check whether each partici-
pant’s income and education are consistent with the high
or low SES group designation made at the initial
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screening. Fourth, implementing regular supervision and
providing feedback will maximize fidelity of decision aid
use. Based on our experience of recording clinic visits, we
are confident that recording 10% of all visits (n = 100) is
realistic and feasible. Finally, regarding Aim 3, if the inter-
ventions do not demonstrate the hypothesized effects and
implementation is not immediately warranted, we will ex-
plore barriers to the intervention’s success, at the patient,
clinician, and system levels.
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